Purpose Most patients with pleuropulmonary paragonimiasis can be cured by the initial single set of Praziquantel (PZQ) treatment. However, several cases have been reported to have unsatisfactory responses to the initial PZQ treatment. The objective of this study was to evaluate the clinical findings of patients with pleuropulmonary paragonimiasis who needed additional PZQ treatment after the 1st set chemotherapy. Patients and Methods Thirty-two patients who were diagnosed with pleuropulmonary paragonimiasis at our institution between 2003 and 2008 were retrospectively reviewed. Results All patients were treated initially with PZQ for 3 days (1st set chemotherapy). Twenty-four patients (75.0%) showed improvement in respiratory symptoms and pulmonary involvements. However, eight patients (25.0%) suffered from relapsed respiratory symptoms and pleural effusion. For these patients, an additional 2nd set PZQ treatment resulted in the resolution of the symptoms and pulmonary involvements. The characteristics of patients who needed multi-set treatments were as follows; longer duration of respiratory symptoms (single vs multi-set treatment group; 6.67 ± 8.08 vs 17.86 ± 11.84 weeks, p=0.009), higher IgG titer (optical density, O.D.) for Pargonimus westermani (ELISA O.D. for PW, 0.54 ± 0.19 vs 0.88 ± 0.16 O.D., p=0.001) and higher frequency of multiple pulmonary lesions (% of patients with multiple lesions; 16.7% vs 50.0%, p=0.059). Conclusion The patients who had a longer duration of respiratory symptoms, higher ELISA titer for PW and/or multiple pulmonary lesions needed an additional PZQ treatment after the 1st set of chemotherapy. Close follow-up after the initial treatment is necessary especially for such patients.
Introduction
Pleuropulmonary paragonimiasis is an illness caused by lung flukes of the genus Paragonimus that are endemic to Southeast Asia, the Indian subcontinent, Central and South America and Africa (1) (2) (3) . In other countries, the disease is most commonly diagnosed in immigrants from endemic countries (4) (5) (6) . Transmission to humans occurs by the ingestion of insufficiently cooked crabs or crayfish that contain the encysted parasite. Multiple infections of paragonimiasis have been recently reported and such multiple infections are likely to increase because of immigration and the internationalization of eating habits (6, 7) . The clinical manifestations of paragonimiasis are varied and a pleural effusion can be revealed (8, 9) . Medical treatment with Praziquantel (PZQ) is the mainstay in the management of pulmonary paragonimiasis. Cure rates approach almost 100% (10, 11) . However, the recent cases with effusion have been reported to have unsatisfactory responses to the initial PZQ treatment (3, 7, 12) . Therefore, we retrospectively reviewed treatment outcomes and clinical findings from the medical records of patients who had pleuropulmonary paragonimiasis with effusion.
Methods
From 2003 to 2008, the medical records of 32 patients who were diagnosed with pleuropulmonary paragonimiasis at the Chonnam National University Hospital were reviewed. The criteria for inclusion as a case of pleuropulmonary paragonimiasis were the patient's seropositivity in a serologic test for Pargonimus westermani and/or the detection of Paragonimus eggs (from the sputum, aspirated pleural effusion or feces), a history of eating raw crabs and/or the clinical manifestations compatible with paragonimiasis (13) , and pleuropulmonary involvement. The compatible manifestations were cough, dyspnea, chest pain, subcutaneous nodules, fever and/or eosinophilia. Duration of symptoms was taken from when the patient first noticed symptoms to their first visit to the hospital. A full clinical evaluation was reviewed for all patients before treatment and this was repeated after treatment. The total leukocyte counts, differential counts and direct eosinophil counts were carried out by standard procedures. A systemic review of the chest radiographs or CT scans was also performed for all patients. A serologic test for Paragonimus westermani parasite-specific IgG by using micro-enzyme linked immunosorbent assay (ELISA for PW) (14, 15) was used for the routine primary screening of parasitic disease.
Thoracentesis was performed in patients with pleural effusion to rule out other diseases. The sputum, stool and pleural effusion of the patients were stained for cytology and then examined for the presence of eggs. They were also stained with Ziehl-Neelsen stain and cultured for acid-fast bacilli. None of the patients had evidence of tuberculosis or malignancy.
All patients were treated with PZQ at a dose of 75 mg/ kg/day for 3 days (1st set treatment). Hematological, serological and chest X-ray examinations were carried out after the course of treatment to evaluate the patient's recovery from the infection. A second set of PZQ medication was given for the patients who had unsatisfactory responses; persistent symptoms, pulmonary involvement, high ELISA titer for PW and/or positive parasite ova in the 2-4 weeks after 1st set treatment.
Statistical software (SPSS, version 17.0; Chicago, IL) was used to compare the differences of characteristics between the single and multi-set PZQ treatment groups. The differences in clinical, laboratory and radiological findings between treatment groups were evaluated using Mann-Whitney and t tests for continuous variables, and χ 2 tests for categorical variables. p values less than 0.05 were considered statistically significant.
Results

Clinical manifestations
Thirty-two patients (17 men and 15 women) diagnosed with pleuropulmonary paragonimiasis had a median age of 44 years (range; 28-63). Of the 32 patients, 30 patients (93.8%) had a history of eating raw foods and especially the freshly salted crabs in Chonnam province. Thirty patients (93.8%) presented with respiratory symptoms: frequent symptoms were productive cough with foul smelling sputum (n=17, 42.5%), dyspnea (n=15, 37.5%) and chest discomfort (n=13, 32.5%). Two patients did not have any symptoms. The other symptoms reported with some frequency included fatigue, pruritus, fever and chills ( Table 1 ). The mean duration of symptoms was 9 weeks (range: 1-40 weeks) when they visited this hospital.
Laboratory findings
Eosinophilia (>500/mm 3 ) was detected in the peripheral blood of most patients (n=31/32, 96.9%). The high serum IgG titer (ELISA O.D. >0.25) for paragonimiasis was strongly detected in all patients. Nineteen patients (73.1%) showed positive reactions on intradermal skin testing for Paragonimus westermani. The sputum (n=24), stool (n=27) and pleural fluid (n=26) were examined for Paragonimus westermani ova from 31 patients. Among them, Paragonimus ova were found in the sputum of three patients (12.5%), and in the stool of two patients (7.4%) and in the pleural fluid of one patient (9.1%). The main laboratory data are shown in Table 1 .
Examination of pleural effusion
The pleural fluid samples were obtained by thoracentesis from 25 patients. Most pleural fluids appeared grossly turbid and yellowish (n=20/25, 80%). The remainder of the patients had serosanguinous or brownish fluid. Most patients had a low pH (80%), an eosinophilic pleural fluid (94.4%) and a very low glucose level (68%). The detailed degree of eosinophilia, the pH level, the LDH and the glucose in the pleural effusions are summarized in Table 2 .
Chest radiograph and CT findings (Fig. 1) We retrospectively reviewed 32 patients' chest radiographs and CT scans that had evidence of pleuropulmonary paragonimiasis with pleural effusion. Pleural effusion was seen unilaterally in 17 patients (53.1%) and bilaterally in 15 patients (46.9%). A small amount of pneumothorax was ob- served concomitantly in fifteen patients (46.9%). Combined intrapulmonary parenchymal lesions included air-space consolidation (n=21, 65.6%), linear opacity (n=11, 34.4 %) and cystic lesions (n=8, 25.0%). Eight patients (25.0%) had 3 or more lobar lesions that were defined as multiple pulmonary lesions in this study.
Treatment and outcomes
The pleural fluid was drained as much as possible by simple needle aspiration (n=23, 92%) or by using a pig-tail catheter (n=2, 8%) for therapeutic purpose as well as for diagnosis. PZQ was administered orally at a dose of 75 mg/ kg/day for 3 days for all patients (1st set treatment). Serious side effects were not noted during medication and thoracentesis. Twenty-four cases (75.0%) had improvement of respiratory symptoms, pulmonary involvement and ELISA titer for PW; ELISA titer waned over time during the follow-up period after treatment (mean ± SD, O.D.; 0.70 ± 0.20 at visit, 0.59 ± 0.15 after 2 mo, 0.31 ± 0.13 after 4 mo, 0.27 ± 0.10 after 6 mo). However, eight patients (25.0%) suffered from relapsed respiratory symptoms, pleural effusion with eosinophilia and a high persistent PW antibody titer after the first management. For these patients, an additional or 2nd set treatment (3 to 7 days of treatment with praziquantel and repeated thoracentesis) resulted in the resolution of the respiratory symptoms and the abnormal findings on chest radiography. All of the patients showed improvement in their symptoms and pleural effusions without surgical decortication or chest tube insertion. The pleural effusion gradually disappeared over a period of several weeks (7.0 ± 4.6 wks) after medication and thoracentesis. These improvements were confirmed during the 6-month to 1-year follow-up period.
The characteristics of single set and multi-set treatment groups are shown in Table 3 . The patients with multi-set treatment had a longer duration of respiratory symptoms, higher titer of PW ELISA (Fig. 2) and a tendency for more multiple pulmonary lesions than the single set treatment group. Eosinophilia in the blood and pleural fluid were significantly lower in the multi-set treatment group.
Discussion
The major finding of this study was that multi-set PZQ treatment may be necessary for the patients with pleuropulmonary paragonimiasis and effusion with special characteristics; a long duration of respiratory symptoms, high PW ELISA titer, etc. Secondary findings were that the outbreak of pleuropulmonary paragonimiasis with pleural effusion is still developing, although local control programs have been able to significantly decrease this rate, and that a variety of clinical and radiological findings were shown in these patients. To our knowledge, this is one of the largest casereview studies on pleuropulmonary paragonimiasis with effusion among the recent publications (3, 7, (16) (17) (18) (19) .
Regarding the treatment of paragonimiasis, PZQ (25 mg/ kg three times a day for 2 to 3 days) is generally considered the current treatment of choice. Most papers have mentioned cure rates of around 90-100%. However, the recent series has reported some treatment failure after an initial set PZQ medication (3, 7, 12) . In the present study, the cure rate was only 75.0% (24/32) after the first set of PZQ and pleural drainage. Our first cure rate was similar to the recent report of Obara and colleagues (cure rate: 81.8%, n=9/11), even though they reviewed only 18 patients with pulmonary or pleural paragomiasis (7). The multi-set treatment group had a longer duration of symptoms and a lower eosinophil level than the single set treatment group in our study. Longer duration of symptoms and a lower eosinophil level could suggest more chronic disease. The degree of peripheral blood eosinophilia decreases when the disease moves into its chronic phase (20) . This chronicity of the disease could be one reason for the requirement for additional doses of PZQ. Another possibility is the density of infection and/or the severity of disease of the patients. Guevara et al (21) and Choi et al (22) reported that there was a correlation of intensity of infection with all antibody and IgG subclasses studied in patients or animals with paragonimiasis (21) . In the present study, Paragonimus ELISA titer and the frequency of multiple pulmonary lesions were higher in the multi-set treatment group. This may indicate that cases of severe disease have the possibility of needing additional multi-set treatment. Our results can be also supported by the report of Obara et al (7) although they reported only 3 cases who had additional sets after 1st set treatment. Among the 3 cases in their report, one patient had bilateral lung lesions and a subcutaneous lesion, another one was a late diagnosis case, 1 year after probable infection with paragonimus and the 3rd patient received the second set medication just for mental reassurance. The first 2 cases are comparable to our multi-set treatment group. According to the above results, the possibility of treatment failure after single set treatment should be considered for the patients who have more prolonged symptoms and/or have multiple pulmonary lesions. Especially for these patients, we should also follow up more closely. Fortunately, in the present study all of the patients were improved after single or multi-set medical treatment so that surgery was not necessary for them. However, duration of 2nd set PZQ medication was varied from 3 days to 7 days. There are no specific criteria to determine the duration of the second treatment and there is no report regarding how long medication is needed in the 2nd set treatment. To our knowledge, this is the first report that compared the characteristics of patients with pleuroplumonary paragonimiasis and effusion between single and multi-set treatment groups. However, a large and prospective study will be needed in the future to confirm the above results and to determine the optimal duration of PZQ medication in the 2nd set treatment.
After conducting a survey on the disease and then treating this illness in South Koreans, the prevalence of human paragonimiasis has decreased by the 1990s (23) . However, in some countries the disease has been re-emerging since the 1980s (7, 24) . The clinical manifestations of paragonimiasis are various; abdominal pain, fever, productive cough, urticaria and recurrent hemoptysis (8, 25, 26) . The present study also showed various symptoms similar to those symptoms elsewhere in the world. Pleuropulmonary paragonimiasis is still developing with various clinical features.
Pleural effusion is frequently observed in cases of paragonimiasis among Indochinese refugees (48%) (6), Koreans (37%) (9) and Japanese (69%) (16) . Most patients with pleural paragonimiasis (6, 27) have significant eosinophilia in their pleural fluid, and their exudates have a low glucose level (less than 10 mg/dL), a low pH (less than 7.10), and a high lactate dehydrogenase level (more than 1,000 IU/L). In the intrapulmonary parenchymal lesions, the radiographic findings include various patterns such as diffuse and segmental infiltrates, consolidations, nodules, cavities and cystic changes (6, 9) . These observations are consistent with our results. Therefore, paragonimiasis should still be considered as a possible diagnosis when abnormal shadows or effusions are found on the chest radiographs and chest CT scans of patients with eosinophilia.
In conclusion, we could treat pleuropulmonary paragonimiasis by medical management with repeated medical treatment if needed. Close follow-up after the 1st set treatment of PZQ, especially for patients with a long duration of respiratory symptoms, high PW ELISA titer and/or multiple pulmonary lesions is necessary. Further study will be needed to determine a better means of management of this disease.
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